Bone marrow as a priming site for T-cell responses to blood-borne antigen

被引:284
作者
Feuerer, M
Beckhove, P
Garbi, N
Mahnke, Y
Limmer, A
Hommel, M
Hämmerling, GJ
Kyewski, B
Hamann, A
Umansky, V
Schirrmacher, V [1 ]
机构
[1] German Canc Res Ctr DKFZ, Tumor Immunol Program, Heidelberg, Germany
[2] Univ Clin, Inst Mol Med & Expt Immunol, Bonn, Germany
[3] Humboldt Univ, Charite, Dept Expt Rheumatol, Berlin, Germany
关键词
D O I
10.1038/nm914
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Although bone marrow is known as a primary lymphoid organ, its potential to serve as a secondary immune organ has hardly been explored. Here we demonstrate that naive, antigen-specific T cells home to bone marrow, where they can be primed. Antigen presentation to T cells in bone marrow is mediated via resident CD11c(+) dendritic cells. They are highly efficient in taking up exogenous blood-borne antigen and processing it via major histocompatibility complex class I and class II pathways. T-cell activation correlates with dendritic cell-T cell clustering in bone marrow stroma. Primary CD4(+) and CD8(+) T-cell responses generated in bone marrow occur in the absence of secondary lymphoid organs. The responses are not tolerogenic and result in generation of cytotoxic T cells, protective anti-tumor immunity and immunological memory. These findings highlight the uniqueness of bone marrow as an organ important for hemato- and lymphopoiesis and for systemic T cell-mediated immunity.
引用
收藏
页码:1151 / 1157
页数:7
相关论文
共 40 条
[1]
Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology [J].
Aichele, P ;
BrduschaRiem, K ;
Oehen, S ;
Odermatt, B ;
Zinkernagel, RM ;
Hengartner, H ;
Pircher, H .
IMMUNITY, 1997, 6 (05) :519-529
[2]
BAIN BJ, 2001, BONE MARROW PATHOLOG, P114
[3]
Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]
Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice [J].
Berlin-Rufenach, C ;
Otto, F ;
Mathies, M ;
Westermann, J ;
Owen, MJ ;
Hamann, A ;
Hogg, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (09) :1467-1478
[5]
Chin R, 2001, NAT MED, V7, P1165, DOI 10.1038/nm1101-1165a
[6]
Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1 [J].
Coles, RM ;
Mueller, SN ;
Heath, WR ;
Carbone, FR ;
Brooks, AG .
JOURNAL OF IMMUNOLOGY, 2002, 168 (02) :834-838
[7]
CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo [J].
den Haan, JMM ;
Lehar, SM ;
Bevan, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (12) :1685-1695
[8]
TARGETING ANTIGEN INTO THE PHAGOCYTIC PATHWAY IN-VIVO INDUCES PROTECTIVE TUMOR-IMMUNITY [J].
FALO, LD ;
KOVACSOVICSBANKOWSKI, M ;
THOMPSON, K ;
ROCK, KL .
NATURE MEDICINE, 1995, 1 (07) :649-653
[9]
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow [J].
Feuerer, M ;
Beckhove, P ;
Bai, LH ;
Solomayer, EF ;
Bastert, G ;
Diel, IJ ;
Pedain, C ;
Oberniedermayr, M ;
Schirrmacher, V ;
Umansky, V .
NATURE MEDICINE, 2001, 7 (04) :452-458
[10]
Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.3.CO